great summary. The oncology panel discussion highlighted Ariad Pharma a smaller biotech that was denied then later granted BTD.
They submitted based on P1 dose escalation n = 16 with 75% ORR but were told by FDA too early. Duration of response for R/R NSCLC was relevant.
At a long shot perhaps the nature of CPACS maybe Race can submit BTD earlier. Being realistic P2 data might be required. If we get it at P1 that is perhaps a massive endorsement from the FDA.
So what happened to Ariad Pharma after that?
No less than $5.2b USD deal and it went quickly.
https://www.forbes.com/sites/antoinegara/2017/01/09/ariads-5-2-billion-sale-to-takeda-nets-260-million-windfall-for-hedge-fund/
- Forums
- ASX - By Stock
- RAC
- CPACS: Research, Results, Market Comparisons, and Valuations
CPACS: Research, Results, Market Comparisons, and Valuations, page-204
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M |
Open | High | Low | Value | Volume |
$1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 15072 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.87 | 1793 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 15072 | 1.780 |
1 | 1690 | 1.775 |
1 | 11200 | 1.770 |
1 | 2200 | 1.760 |
1 | 569 | 1.755 |
Price($) | Vol. | No. |
---|---|---|
1.870 | 1793 | 1 |
1.880 | 2351 | 1 |
1.890 | 1000 | 1 |
1.895 | 7800 | 1 |
1.950 | 30264 | 5 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online